Key Highlights
- Jacobs has been selected as the Engineering, Procurement and Construction Management partner for Sanofi’s new insulin Facility in Frankfurt.
- The scope covers design, procurement, construction management and commissioning, with the plant located alongside Sanofi’s existing insulin campus.
- Jacobs was ranked No. 1 Pharmaceuticals Design Firm by Engineering News-Record earlier in 2026.
- The company reports approximately US$12 billion in annual Revenue and about 47,000 employees worldwide.
Jacobs (NYSE:J) has been selected by Sanofi as the Engineering, Procurement and Construction Management (EPCM) partner for a new insulin Manufacturing facility in Frankfurt, Germany. The facility will be located alongside Sanofi’s established insulin manufacturing campus and will support the production of multiple insulin products. Financial terms of the award were not disclosed in the announcement.
Scope of the Frankfurt Project
Jacobs will provide integrated EPCM services spanning design, procurement, construction management and commissioning. The company said its involvement during early project development will carry into delivery, using existing site infrastructure and advanced manufacturing technologies. The project is described as a modernization of insulin manufacturing intended to support Supply reliability. The company said the new facility will incorporate advanced manufacturing systems intended to support efficient and reliable operations, and that it will use infrastructure already in place at Sanofi’s Frankfurt campus.
To deliver the work, Jacobs plans to deploy an integrated team covering engineering, procurement, project controls, construction management, commissioning, quality and safety, from design through startup. The announcement did not include a construction timeline or a contract value.
Life Sciences and German Project Record
Jacobs Executive Vice President Sean Sommer pointed to the company’s life sciences history, which dates to 1943, when founder Dr. Joe Jacobs was part of the team that enabled the first commercial-scale production of penicillin. Engineering News-Record ranked Jacobs the No. 1 Pharmaceuticals Design Firm earlier this year. The company also cited its EPCM role on FUJIFILM Biotechnologies’ US$3.2 billion Holly Springs campus, described as one of the largest biomanufacturing facilities in North America. Sommer said the company continues to deliver the advanced manufacturing facilities behind important therapies more than 80 years later, and Jacobs said the award reinforces its position as a provider to global pharmaceutical and biotechnology manufacturers.
In Germany, Jacobs listed recent work that includes SuedLink, an underground high-voltage power cable project; a framework with TransnetBW supporting grid expansion and the energy transition; and thyssenkrupp Steel’s industrial decarbonization program. The company has more than 300 employees across three offices in Germany, with services spanning life sciences, energy, infrastructure and advanced manufacturing. Jacobs stated that its German work is intended to support innovation, resilience and long-term economic growth.
Company Profile and Disclosed Risks
Jacobs describes itself as providing end-to-end services in advanced manufacturing, cities and places, energy, environmental, life sciences, transportation and water. It reports approximately US$12 billion in annual revenue and a team of approximately 47,000. Its services range from advisory and consulting, feasibility and planning through design and program and lifecycle management.
The announcement included forward-looking statement language listing factors that could cause results to differ from expectations. These include the timing of project awards and funding, changes to amounts provided under the Infrastructure Investment and Jobs Act and other legislation, directives to reduce federal spending, changes in tax laws, tariffs and trade policies, inflation, interest rates, foreign currency exchange rates, Capital Markets conditions, the possibility of a recession, election outcomes in key markets and geopolitical tension. The company stated that it is not under a duty to update such statements except as required by law. The statements are based on management’s current estimates and expectations, including competitive, financial and economic data, and the company noted that such statements are inherently uncertain. It directed readers to its filings with the U.S. Securities and Exchange Commission for a description of additional factors.
The Bottom Line
The Sanofi award adds a Frankfurt insulin facility to Jacobs’ list of life sciences and German infrastructure projects. The announcement provided scope and background details but no revenue, contract value or schedule, and it carried the company’s standard forward-looking statement cautions. Later company disclosures may show how the project is reflected in reported results.




_11_19_2026_12_02_00_557011.jpg)

Please wait processing your request...